ClinicalTrials.gg
CompletedNCT02561078VIVIDUpdated May 20, 2020Results posted

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Human regular U-500 insulin (CSII) and Human regular U-500 insulin (MDI) in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
10th of 49
420 · median 129
Started
2015
with 1 other
Phase 3
25 of 49
none open now
Registered
42nd of 49
by date
Lead sponsor
7 of 49
Eli Lilly and Company

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2015, is one of 25 in phase 3, and was the 42nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2 diabetes mellitus.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • insulin pumps
  • concentrated insulin
  • OmniPod
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes mellitus (T2DM).
  • Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry.

    • If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD.
  • ≥7.5% and ≤12.0%.
  • ≥25 but ≤50 kilograms per meter squared.
  • Have a history of stable body weight.
  • Concomitant antihyperglycemic agent (AHA) therapy may include metformin (MET), dipeptidyl peptidase-4 inhibitors and/or pioglitazone.

    • Approximately 64 to 96 subjects using glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitors will be enrolled in Study Group B.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with type 1 diabetes mellitus (T1DM) or other types of diabetes apart from T2DM.
  • Have obvious clinical or radiographic signs or symptoms of liver disease (except nonalcoholic fatty liver disease), cirrhosis, acute or chronic hepatitis, or (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) levels ≥2.5X (ULN), alkaline phosphatase ≥2X ULN or total ≥2X ULN.
  • Have chronic kidney disease Stage 4 and higher or history of renal transplantation.
  • Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to screening.
  • Have received U-500R insulin by CSII in the 3 months prior to screening.
  • Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
  • Are taking chronic (lasting longer than 14 consecutive days) systemic therapy.
  • Have an irregular sleep/wake cycle.
  • Have used any weight loss drugs in the 3 months prior to screening.
  • Have a history of bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve.
  • Have a history of an active or untreated , or in remission from a malignancy during the last 5 years before screening.
  • Significant hearing loss and/or vision impairment deemed by the investigator to interfere with the safe use of OmniPod U-500 system.
  • Have cardiac disease with functional status that is (NYHA) Class III or IV per New York Heart Association Cardiac Disease Functional Classification or have congestive heart failure requiring pharmacologic treatment.
  • Are women breastfeeding or pregnant, or intend to become pregnant during the course of the study; are men who intend to impregnate their partners; or are sexually active of procreation potential not actively practicing by a method determined by the investigator to be medically acceptable. Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    Human regular U-500 insulin administered by CSII

    Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.

    Drug: Human regular U-500 insulin (CSII)

  • Active comparator
    Human regular U-500 insulin administered by MDI

    Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.

    Drug: Human regular U-500 insulin (MDI)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

    Time frame: Baseline, 26 Weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Fasting plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

    Time frame: Baseline, 26 Weeks

  2. Percentage of Participants With HbA1c <7.0%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.0% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

    Time frame: 26 Weeks

  3. Percentage of Participants With HbA1c <7.5%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.5% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

    Time frame: 26 Weeks

  4. Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values

    Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.

    Time frame: Baseline, 26 Weeks

  5. Change From Baseline in Total Daily Dose (TDD)

    Baseline TDD was defined as the last prestudy insulin TDD prior to randomization to receiving the first dose of U-500 insulin post randomization. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.

    Time frame: Baseline, 26 Weeks

  6. Percentage of Participants With Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)

    The percentage of participants with hypoglycemic episodes (documented hypoglycemia) was calculated by dividing the number of participants with at least 1 hypoglycemic episode (documented hypoglycemia) over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. Logistic regression was used to estimate the odds ratio between the two treatments of at least 1 hypoglycemic episode (documented hypoglycemia) over 26 week treatment period adjusted for baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.

    Time frame: 26 Weeks

  7. Rate of Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)

    Documented Hypoglycemic episodes with blood glucose\<=70mg/dL was used in this outcome measure. Hypoglycemia rate (documented hypoglycemia) per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia (documented hypoglycemia) was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, with log of exposure in days divided by 30 as the offset, treatment, visit, and visit by treatment interaction.

    Time frame: Baseline to 26 Weeks

  8. Change From Baseline in Body Weight

    Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, treatment by time interaction.

    Time frame: Baseline, 26 Weeks

07

Results

Posted May 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Started209211
Received at least 1 dose of study drug208210
Completed179186
Not completed3025
Withdrew: Adverse event52
Withdrew: Death21
Withdrew: Lost to follow-up26
Withdrew: Non-compliance with study drug63
Withdrew: Physician decision23
Withdrew: Withdrawal by subject1310

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1cHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Change From Baseline in Hemoglobin A1c (HbA1c)-1.27 ± 0.072-0.85 ± 0.070
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.42 · 95% CI -0.62 to -0.22
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Fasting plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG)
milligrams per deciliter (mg/dL)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Change From Baseline in Fasting Plasma Glucose (FPG)-33.9 ± 5.031.7 ± 4.90
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = <0.001 · Mean difference (net): -35.6 · 95% CI -49.4 to -21.7
SecondaryPercentage of Participants With HbA1c <7.0%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.0% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

Time frame:
26 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c <7.0%
Percentage of participantsHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Percentage of Participants With HbA1c <7.0%28.6518.44
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Regression, Logistic · p = 0.015 · Odds ratio (or): 1.97 · 95% CI 1.14 to 3.39
SecondaryPercentage of Participants With HbA1c <7.5%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Longitudinal logistic regression was used to model the likelihood of having hbA1c\<7.5% at Week 26 with baseline of response, glucagon-like peptide-1 (GLP-1) or sodium-glucose cotransporter 2 (SGLT2) use, U-500R at entry, treatment, time and treatment by time interaction.

Time frame:
26 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With HbA1c <7.5%
Percentage of ParticipantsHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Percentage of Participants With HbA1c <7.5%52.6338.55
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Regression, Logistic · p = 0.005 · Odds ratio (or): 1.94 · 95% CI 1.23 to 3.07
SecondaryChange From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values

Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values
mg/dLHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Pre Morning Meal-34.3 ± 3.53-11.8 ± 3.41
2 Hours Post Morning Meal-25.0 ± 4.58-7.8 ± 4.50
Pre Mid-Day Meal-19.8 ± 4.29-10.9 ± 4.15
2 Hours Post Mid-Day Meal-8.3 ± 4.20-16.6 ± 4.08
Pre Evening Meal-15.1 ± 4.11-24.3 ± 3.99
2 HOURS POST EVENING MEAL-14.6 ± 4.19-31.3 ± 4.02
OVERNIGHT (3:00 AM)-25.4 ± 3.71-26.0 ± 3.58
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = <0.001 · Mean difference (net): -22.5 · 95% CI -32.1 to -12.8
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.008 · Mean difference (net): -17.2 · 95% CI -29.9 to -4.6
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.138 · Mean difference (net): -8.9 · 95% CI -20.6 to 2.9
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.160 · Mean difference (net): 8.3 · 95% CI -3.3 to 19.8
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.113 · Mean difference (net): 9.1 · 95% CI -2.2 to 20.4
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.004 · Mean difference (net): 16.7 · 95% CI 5.3 to 28.2
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.905 · Mean difference (net): 0.6 · 95% CI -9.5 to 10.8
SecondaryChange From Baseline in Total Daily Dose (TDD)

Baseline TDD was defined as the last prestudy insulin TDD prior to randomization to receiving the first dose of U-500 insulin post randomization. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · units/day
Change From Baseline in Total Daily Dose (TDD)
units/dayHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Change From Baseline in Total Daily Dose (TDD)2.8 ± 9.3351.3 ± 9.14
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = <0.001 · Mean difference (net): -48.4 · 95% CI -74.1 to -22.8
SecondaryPercentage of Participants With Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)

The percentage of participants with hypoglycemic episodes (documented hypoglycemia) was calculated by dividing the number of participants with at least 1 hypoglycemic episode (documented hypoglycemia) over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. Logistic regression was used to estimate the odds ratio between the two treatments of at least 1 hypoglycemic episode (documented hypoglycemia) over 26 week treatment period adjusted for baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, time and treatment by time interaction.

Time frame:
26 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)
Percentage of ParticipantsHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Percentage of Participants With Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)95.6995.71
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Regression, Logistic · p = 0.919 · Odds ratio (or): 1.05 · 95% CI 0.39 to 2.86
SecondaryRate of Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)

Documented Hypoglycemic episodes with blood glucose\<=70mg/dL was used in this outcome measure. Hypoglycemia rate (documented hypoglycemia) per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia (documented hypoglycemia) was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline documented hypoglycemia rate, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, with log of exposure in days divided by 30 as the offset, treatment, visit, and visit by treatment interaction.

Time frame:
Baseline to 26 Weeks
Reported as:
Least squares mean · Episodes/participant/30 days
Rate of Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)
Episodes/participant/30 daysHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Rate of Hypoglycemic Episodes (Documented Hypoglycemia With Blood Glucose <= 70 mg/dL)5.16 ± 0.3804.27 ± 0.308
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Negative binomial regression · p = 0.025 · Relative rate: 1.21 · 95% CI 1.02 to 1.42
SecondaryChange From Baseline in Body Weight

Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, GLP-1 or SGLT2 use, U-500R at entry, baseline HbA1C group, treatment, treatment by time interaction.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · Kilograms (kg)
Change From Baseline in Body Weight
Kilograms (kg)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Change From Baseline in Body Weight4.2 ± 0.353.4 ± 0.34
Statistical analysis
  • Human Regular U-500 Insulin Administered by CSII vs Human Regular U-500 Insulin Administered by MDI · Mixed Models Analysis · p = 0.100 · Mean difference (net): 0.8 · 95% CI -0.2 to 1.8

Adverse events

Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Human Regular U-500 Insulin Administered by CSII2/209 (1%)34/209 (16.3%)85/209 (40.7%)
Human Regular U-500 Insulin Administered by MDI1/211 (0.5%)23/211 (10.9%)84/211 (39.8%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
HypoglycaemiaMetabolism and nutrition disorders10/2095/211
PneumoniaInfections and infestations4/2092/211
SepsisInfections and infestations3/2090/211
Acute kidney injuryRenal and urinary disorders1/2093/211
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2093/211
Cardiac failure congestiveCardiac disorders2/2090/211
Cerebrovascular accidentNervous system disorders2/2090/211
Non-cardiac chest painGeneral disorders1/2092/211
Acute coronary syndromeCardiac disorders1/2090/211
Acute myocardial infarctionCardiac disorders1/2090/211
Most frequent other events
Showing 10 of 11
Most frequent other events
EventHuman Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDI
Upper respiratory tract infectionInfections and infestations17/20918/211
Viral upper respiratory tract infectionInfections and infestations11/20918/211
DiarrhoeaGastrointestinal disorders14/20917/211
NauseaGastrointestinal disorders9/20917/211
Weight increasedInvestigations14/20913/211
HeadacheNervous system disorders9/20914/211
SinusitisInfections and infestations10/20913/211
Back painMusculoskeletal and connective tissue disorders11/20913/211
CoughRespiratory, thoracic and mediastinal disorders7/20912/211
HyperglycaemiaMetabolism and nutrition disorders11/2090/211

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDITotal
Mean57.58 ± 10.2756.66 ± 10.1257.12 ± 10.19
Sex: Female, Male
Sex: Female, Male(Participants)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDITotal
Female10594199
Male104117221
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDITotal
Hispanic or Latino394988
Not Hispanic or Latino170162332
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDITotal
American Indian or Alaska Native123
Asian279
Native Hawaiian or Other Pacific Islander123
Black or African American191433
White160160320
More than one race252651
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDITotal
Puerto Rico152136
United States194190384
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)Human Regular U-500 Insulin Administered by CSIIHuman Regular U-500 Insulin Administered by MDITotal
Mean8.75 ± 1.038.77 ± 1.088.76 ± 1.05
08

Study locations

57 sites
  • Internal Medicine Center LLC
    Mobile, Alabama 36608, United States
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Valley Endocrine, Fresno
    Fresno, California 93720, United States
  • Scripps Whittier Diabetes Institute
    La Jolla, California 92037, United States
  • Diabetes and Endocrine Associates
    La Mesa, California 91942, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • NorCal Endocrinology and Internal Medicine - Roseville
    Roseville, California 95661, United States
  • NorCal Endocrinology and Internal Medicine - Roseville
    San Ramon, California 94583, United States
  • Olive View Medical Center
    Sylmar, California 91342, United States
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • East Coast Institute For Research, LLC
    Jacksonville, Florida 32216, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Metabolic Research Institute Inc.
    West Palm Beach, Florida 33401, United States
  • East Coast Institute For Research, LLC
    Macon, Georgia 31210, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • John H. Stroger Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Midwest CRC
    Crystal Lake, Illinois 60012, United States
  • HSHS Medical Group Diabetes Research
    Springfield, Illinois 62711, United States
  • Iderc, P.L.C.
    Des Moines, Iowa 50314, United States
  • Cotton O'Neil Diabetes and Endocrinology Center
    Topeka, Kansas 66606, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503, United States
  • The Arthritis & Diabetes Clinic Inc.
    Monroe, Louisiana 71203, United States
  • Grunberger Diabetes Institute
    Bloomfield Hills, Michigan 48302, United States
  • Adult Endocrinology Consultants, P.C.
    Livonia, Michigan 48154, United States
  • JCMG Clinical Research
    Jefferson City, Missouri 65109, United States
  • Billings Clinic Research Center
    Billings, Montana 59101, United States
  • Diabetes and Endocrinology Associates
    Omaha, Nebraska 68114, United States
  • Palm Research Center
    Las Vegas, Nevada 89128, United States
  • Palm Research Center
    Las Vegas, Nevada 89148, United States
  • Southern New Hampshire Diabetes and Endocrinology
    Nashua, New Hampshire 03063, United States
  • North Shore Diabetes and Endocrine Assoc
    New Hyde Park, New York 11040, United States
  • Mountain Diabetes and Endocrine Center
    Asheville, North Carolina 28803, United States
  • Physicians East
    Greenville, North Carolina 27834, United States
  • PMG Research of Rocky Mount, LLC
    Rocky Mount, North Carolina 27804, United States
  • University of Oklahoma Health Sciences Center-Tulsa
    Oklahoma City, Oklahoma 73104, United States
  • Portland Diabetes & Endocrine Center
    Portland, Oregon 97210, United States
  • Endocrine Metabolic Associates, P.C.
    Philadelphia, Pennsylvania 19114, United States
  • Partners in Nephrology & Endocrinology
    Pittsburgh, Pennsylvania 15224, United States
  • Sudhir Bansal M.D. Inc.
    Warwick, Rhode Island 02886, United States
  • AM Diabetes and Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • University Diabetes and Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
  • Vanderbilt Univeristy School of Medicine
    Nashville, Tennessee 37232, United States
  • Texas Diabetes and Endocrinology-Austin South
    Austin, Texas 78749, United States
  • Dallas Diabetes Endocrine Center
    Dallas, Texas 75230, United States
  • Texas Diabetes and Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • Advanced Research Institute
    South Ogden, Utah 84405, United States
  • Dr. Larry Stonesifer
    Federal Way, Washington 98003, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Northside Internal Medicine
    Spokane, Washington 99208, United States
  • Multicare Health System
    Tacoma, Washington 98405, United States
  • Dr Altagracia Aurora Alcantara Gonzalez
    Bayamon, 00956, Puerto Rico
  • Manati Center for Clinical Research Inc
    Manati, 00674, Puerto Rico
  • Endocrine Lipid Diabetes Research Institute
    Ponce, 00717, Puerto Rico
  • American Telemedicine Center
    San Juan, 00917, Puerto Rico
  • Martha Gomez Cuellar M.D.
    San Juan, 00921, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in May 2017, 18 months.

Results were first posted in May 2020, 3 years after primary completion. A results delay was requested in May 2018.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2015
First posted
Sep 25, 2015
StartActual
Oct 20, 2015
Primary completionActual
May 9, 2017
CompletionActual
May 9, 2017
Results delay requested
May 4, 2018
Results first posted
May 20, 2020
Last update
May 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02561078
Collaborators
Insulet Corporation
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
Oct 20, 2015
Primary completion
May 9, 2017
Completion
May 9, 2017
Results posted
May 20, 2020
Last update
May 20, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion